Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations

Renal Cell Carcinoma Tweetorial

Certification period for this program has expired.
No credit will be offered beyond the program dates noted on the bottom of this page.


This activity is jointly provided by Global Education Group and Bonum CE in partnership with Tumor Board Tuesday.

Supported by an educational grant from Eisai Inc. and Merck Sharp & Dohme LLC.

Program Overview

In partnership with Tumor Board Tuesday, this CME-certified, Tweetorial reviews the latest data related to anti-angiogenic therapies and immune checkpoint inhibitors in Renal Cell Carcinoma (RCC). An assessment of associated toxicities of these agents will lead learners to evaluate how these toxicities may impact treatment selection and management.

Faculty

Brian Rini, MD (program chair)
Professor of Medicine
Division of Hematology and Oncology
Vanderbilt University Medical Center
Nashville, TN

Kathryn Beckermann, MD, PhD
Assistant Professor of Medicine
Division of Hematology and Oncology
Vanderbilt University Medical Center
Nashville, TN

Shilpa Gupta, MD
Associate Professor
Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Target Audience

This program is primarily intended for oncologists and other HCPs involved in the care and management of patients with RCC.

Learning Objectives

After completing this activity series, the participant should be better able to:

  • EXPRESS awareness of AEs associated with anti-angiogenic therapy and how they differ from immune-mediated AEs

  • DIFFERENTIATE etiology and presentation of overlapping toxicities with AA/IO combination therapy

  • SELECT optimal strategies to prevent and manage common AEs experienced by patients treated with AA/IO combination therapy

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

 

  • Brian Rini, MD
    Consulting: Alkermes, Allogene Therapeutics, Arrowhead, Aravive, Athenex, AVEO, Bristol Myers Squibb, Corvus, Debiopharm, Eisai, EUSA, GNE/Roche, Merck, Nikang Therapeutics, Pfizer, Shionogi, Surface Oncology, Synthorx
    Contracted Research: Aravive, Arrowhead Pharmaceuticals, AstraZeneca, AVEO, Bristol Myers Squibb, Exelixis, Hoffman-LaRoche, Immunomedics, Incyte, Janssen, Merck, Mirati Therapeutics, Pionyr, Pfizer, Seattle Genetics, Surface Oncology
    Stock Shareholder: PTC Therapeutics

    Kathryn Beckermann, MD, PhD
    Consulting: Alpine, Aravive, AstraZeneca, AVEO, Bristol Myers Squibb, Exelixis, Merck
    Contracted Research: Alpine, Aravive, Arrowhead, Arsenal, AVEO, Bristol Myers Squibb, Exelexis, Merck, Pionyr, Xcovery

    Shilpa Gupta, MD
    Consulting: Bayer, Bristol Myers Squibb, EMD Serono, Gilead, Guardant, Loxo Oncology, Merck, Natera, Pfizer, Seattle Genetics
    Contracted Research: Bristol Myers Squibb, EMD Serono, Exelixis, Genentech, Gilead, Merck, Moderna, Novartis, Pfizer, QED, Seattle Genetics
    Speakers’ Bureau: Bristol Myers Squibb, Gilead, Janssen, Seattle Genetics
    Stock Shareholder: BioNTech, Moderna

  • Lindsay Borvansky
    Nothing to disclose

    Ashley Cann
    Nothing to disclose

    Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Certification

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Bonum Continuing Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Release date: December 12, 2022
Expiration date: December 12, 2023
Estimated time to complete activity: 15 minutes